GET HELP NOW

Thursday, November 9, 2017

Th1/17 hybrid T cells offer potent and durable anti-tumor response in preclinical model

http://ift.tt/eA8V8J Adoptive cell therapy for cancer involves harvesting T cells from a patient and expanding and sometimes modifying them in the laboratory before reinfusion. It has been challenging to create T cells that are both potent and durable. In a new study, researchers report the potent anti-tumor properties of hybrid Th1/Th17 cells that combine the cancer-fighting properties of Th1 cells and the ability of Th17 cells to self-renew and regenerate.

from http://ift.tt/2ylEmw3
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...